Predictmedix Advances Commercialization Plans for its AI-powered Technology Suite in Key Asian Markets

  • Key ongoing discussions with Government officials for scaling Safe Entry's multiple healthcare applications
  • Ongoing partnership with prestigious Indonesian university for validation of Safe Entry as part of medical device regulatory approval process
  • Significant updates to Safe Entry's technology suite and broad healthcare applications

TORONTO, ON / ACCESSWIRE / June 13, 2023 / Predictmedix Inc. ("Predictmedix" or the "Company") (CSE:PMED)(OTCQB:PMEDF)(FRA:3QP), a leading provider of rapid health screening solutions powered by proprietary artificial intelligence (AI), is making significant strides in the commercialization of its AI-product suite in key Asian markets. The company is pleased to announce substantial progress in its ongoing partnership with a prestigious Indonesian university, as it advances through the validation process for regulatory approval of its AI-product suite as a medical device in Indonesia. Additionally, Predictmedix has actively engaged with government officials from the technology sector to explore the extensive healthcare applications of its Safe Entry solution at a scalable level.

Over the past three weeks, Predictmedix has had the privilege of working closely with government officials with the aim to explore diverse applications using the company's AI products and technology which can integrate seamlessly into pre-existing systems for rapid scalability. Furthermore, Predictmedix's ongoing partnership with key Indonesian university plays a pivotal role in its commercialization plan throughout lucrative Asian regions.

Through comprehensive testing and analysis, the company aims to demonstrate the efficacy and accuracy of its AI technology and products in diagnosing a broad range of medical conditions and screening for key vitals as part of standard operating procedures in healthcare. Predictmedix's partnership with the university has been essential in advancing its AI-powered technology applications and providing access to diverse patient populations, enabling real-world validation of its cutting-edge solutions.

Obtaining regulatory approval for medical devices is an integral aspect of any product prior to being commercialized in healthcare settings. As part of the Predictmedix's commercialization plan, regulatory approval for the company's suite of AI-products in Indonesia is underway. The company is committed to meeting rigorous industry standards and regulations and is confident in obtaining regulatory approval, building on its track record of successful regulatory compliance.

"We are excited to announce the significant progress we have made in our collaboration with the Indonesian university and our ongoing discussions with government officials," commented Dr. Rahul Kushwah, COO of Predictmedix. "This partnership is a game-changer for us as we advance the validation and commercialization of our AI-powered medical device suite in promising markets. By obtaining regulatory approval, we are taking a giant leap towards bringing cutting-edge technology to healthcare organizations, revolutionizing patient care, and optimizing healthcare processes. With our commitment to meeting industry standards and regulations, we are confident in our ability to deliver innovative solutions that will reshape the healthcare landscape and drive positive impact."

Predictmedix's advancements in its commercialization plans, strategic collaborations, and dedication to regulatory compliance position the Company as a leader in the Asian healthcare market. With significant updates to its Safe Entry technology suite and a wide range of healthcare applications, Predictmedix is poised to transform the delivery of healthcare services, improving patient outcomes, and enhancing operational efficiency. As the Company continues to progress its commercialization strategy, it aims to remain at the forefront of AI-driven healthcare innovation, committed to reshaping the industry and driving positive change.

About Predictmedix Inc.
Predictmedix (CSE:PMED) (OTCQB:PMEDF) (FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations - powered by a proprietary artificial intelligence (AI) - use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including infectious diseases such as COVID-19, impairment by drugs or alcohol, fatigue or various mental illnesses. Predictmedix's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at www.Predictmedix.com or follow us on Twitter, Instagram or LinkedIn.

Public Relations Contact
For further media information or to set up an interview, please contact:

Nelson Hudes
Hudes Communications International
(905) 660 9155

Nelson@hudescommunications.com
Dr. Rahul Kushwah
(647) 889 6916

Caution Regarding Forward-Looking Information:
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time."

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE: PredictMedix Inc.



View source version on accesswire.com:
https://www.accesswire.com/760826/Predictmedix-Advances-Commercialization-Plans-for-its-AI-powered-Technology-Suite-in-Key-Asian-Markets

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.